SPRO
Spero Therapeutics, Inc.
Price Chart
Latest Quote
$2.28
+0.17 (+8.06%)
Current Price
| Previous Close | $2.11 |
| Open | $2.50 |
| Day High | $2.51 |
| Day Low | $2.15 |
| Volume | 7,106,033 |
Stock Information
| Shares Outstanding | 57.90M |
| Total Debt | $2.47M |
| Cash Equivalents | $56.13M |
| Revenue | $61.19M |
| Net Income | $15.23M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $132.02M |
| P/E Ratio | 8.44 |
| EPS (TTM) | $0.27 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $106.73M |
| Sales | $61.19M |
| Income | $15.23M |
| Book/sh | $1.05 |
| Cash/sh | $0.97 |
| Employees | 25 |
Financial Ratios
| Quick Ratio | 10.23 |
| Current Ratio | 10.50 |
| Debt/Eq | 4.67 |
Returns & Margins
| ROA | 12.96% |
| ROE | 35.12% |
| Gross Margin | 54.61% |
| Operating Margin | -2921.70% |
| Profit Margin | 24.90% |
Ownership
| Insider Ownership | 22.52% |
| Institutional Ownership | 16.11% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.05 |
| P/S | 2.16 |
| P/B | 2.18 |
Analyst Data
| Recommendation | hold |
| Target Price | $4.00 |
Technical Indicators
| SMA20 | $2.73 |
| SMA50 | $2.68 |
| SMA200 | $2.40 |
| RSI | 36.18 |
| ATR | 0.2624 |
| Shares Float | 46.52M |
| Short Float | 3.56% |
| Short Ratio | 2.32 |
| Volatility | 1.46 |
| Rel Volume | 4.07 |
Performance History
| Week | -15.56% |
| Month | -11.97% |
| Quarter | -7.69% |
| 6 Months | +0.44% |
| YTD | -2.98% |
| Year | -21.38% |
| 3 Years | +32.56% |
| 5 Years | -85.21% |
| 10 Years | -80.17% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.28 | 7,164,400 |
| 2026-06-17 | $2.11 | 11,185,600 |
| 2026-06-16 | $2.77 | 1,432,200 |
| 2026-06-15 | $2.91 | 934,400 |
| 2026-06-12 | $2.85 | 623,700 |
| 2026-06-11 | $2.70 | 1,156,400 |
| 2026-06-10 | $2.54 | 762,500 |
| 2026-06-09 | $2.57 | 1,129,100 |
| 2026-06-08 | $2.74 | 649,000 |
| 2026-06-05 | $2.82 | 756,300 |
| 2026-06-04 | $2.98 | 1,026,100 |
| 2026-06-03 | $2.80 | 775,500 |
| 2026-06-02 | $2.83 | 606,000 |
| 2026-06-01 | $2.83 | 649,000 |
| 2026-05-29 | $2.83 | 1,338,900 |
| 2026-05-28 | $2.90 | 790,900 |
| 2026-05-27 | $2.93 | 1,773,900 |
| 2026-05-26 | $2.86 | 1,516,000 |
| 2026-05-22 | $2.76 | 545,500 |
| 2026-05-21 | $2.69 | 433,200 |
| 2026-05-20 | $2.63 | 320,200 |
| 2026-05-19 | $2.59 | 323,200 |
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)
InvestorsHub âĸ 2026-06-18T13:52:58Z
Promising Penny Stocks To Consider In May 2026
Simply Wall St. âĸ 2026-05-15T12:05:13Z
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
Exec Edge âĸ 2026-04-22T22:03:19Z
Uncovering 3 Penny Stocks With Market Caps Under $700M
Simply Wall St. âĸ 2026-04-08T18:05:19Z
Airgain And 2 Other Promising Penny Stocks
Simply Wall St. âĸ 2026-02-05T18:06:00Z
3 Promising Penny Stocks With Market Caps Up To $300M
Simply Wall St. âĸ 2026-01-07T18:05:46Z
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2025-12-15T10:20:03Z
3 Promising Penny Stocks With Market Caps Over $20M
Simply Wall St. âĸ 2025-11-04T18:05:11Z
Best Momentum Stock to Buy for October 10th
Zacks âĸ 2025-10-10T14:00:00Z
October 2025's Promising Penny Stocks To Consider
Simply Wall St. âĸ 2025-10-06T18:05:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $59,619,000 | $27,396,000 | $96,735,000 | $48,579,000 |
| Operating Revenue | $59,619,000 | $27,396,000 | $96,735,000 | $48,579,000 |
| Expenses | ||||
| Total Expenses | $52,460,000 | $99,880,000 | $69,948,000 | $79,146,000 |
| Other Income Expense | $-838,000 | $-817,000 | $-5,320,000 | $-14,349,000 |
| Other Non Operating Income Expenses | $7,000 | $60,000 | $-14,000 | $-3,636,000 |
| Net Non Operating Interest Income Expense | $2,512,000 | $4,735,000 | $3,937,000 | $-1,499,000 |
| Operating Expense | $52,460,000 | $99,880,000 | $69,948,000 | $79,146,000 |
| Other Operating Expenses | $-7,183,000 | $-20,581,000 | $-7,046,000 | $-4,930,000 |
| General And Administrative Expense | $21,176,000 | $23,704,000 | $25,554,000 | $36,483,000 |
| Interest Expense | - | - | $0 | $2,605,000 |
| Interest Expense Non Operating | - | - | $0 | $2,605,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Net Interest Income | $2,512,000 | $4,735,000 | $3,937,000 | $-1,499,000 |
| Interest Income | $2,512,000 | $4,735,000 | $3,937,000 | $1,106,000 |
| Normalized Income | $9,391,650 | $-67,689,000 | $27,570,788 | $-35,702,000 |
| Net Income From Continuing And Discontinued Operation | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Total Operating Income As Reported | $6,314,000 | $-73,361,000 | $21,481,000 | $-42,197,000 |
| Net Income Common Stockholders | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Net Income | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Net Income Including Noncontrolling Interests | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Net Income Continuous Operations | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Pretax Income | $8,833,000 | $-68,566,000 | $25,404,000 | $-46,415,000 |
| Special Income Charges | $-845,000 | $-877,000 | $-5,306,000 | $-11,630,000 |
| Interest Income Non Operating | $2,512,000 | $4,735,000 | $3,937,000 | $1,106,000 |
| Operating Income | $7,159,000 | $-72,484,000 | $26,787,000 | $-30,567,000 |
| Per Share | ||||
| Diluted EPS | $0.15 | $-1.27 | $0.43 | $-1.23 |
| Basic EPS | $0.15 | $-1.27 | $0.43 | $-1.23 |
| Other | ||||
| Tax Effect Of Unusual Items | $-25,350 | $0 | $-541,212 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $8,004,000 | $-71,605,000 | $32,460,000 | $-32,228,000 |
| Total Unusual Items | $-845,000 | $-877,000 | $-5,306,000 | $-10,713,000 |
| Total Unusual Items Excluding Goodwill | $-845,000 | $-877,000 | $-5,306,000 | $-10,713,000 |
| Reconciled Depreciation | $0 | $2,000 | $367,000 | $869,000 |
| EBITDA (Bullshit earnings) | $7,159,000 | $-72,482,000 | $27,154,000 | $-42,941,000 |
| EBIT | $7,159,000 | $-72,484,000 | $26,787,000 | $-43,810,000 |
| Diluted Average Shares | $59,039,225 | $54,037,917 | $52,989,030 | $37,585,075 |
| Basic Average Shares | $56,020,363 | $54,037,917 | $52,703,467 | $37,585,075 |
| Diluted NI Availto Com Stockholders | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Tax Provision | $261,000 | $0 | $2,598,000 | $0 |
| Write Off | $587,000 | $0 | $5,306,000 | $0 |
| Restructuring And Mergern Acquisition | $258,000 | $877,000 | $0 | $11,630,000 |
| Research And Development | $38,467,000 | $96,757,000 | $51,440,000 | $47,593,000 |
| Selling General And Administration | $21,176,000 | $23,704,000 | $25,554,000 | $36,483,000 |
| Other Gand A | $9,384,000 | $10,516,000 | $10,230,000 | $16,050,000 |
| Salaries And Wages | $11,792,000 | $13,188,000 | $15,324,000 | $20,433,000 |
| Impairment Of Capital Assets | - | $0 | $5,306,000 | $0 |
| Other Special Charges | - | - | - | $3,581,000 |
| Gain On Sale Of Security | - | - | - | $917,000 |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $59,021,000 | $46,123,000 | $106,894,000 | $75,934,000 |
| Total Assets | $68,919,000 | $110,543,000 | $182,390,000 | $124,802,000 |
| Total Non Current Assets | $1,633,000 | $3,267,000 | $51,182,000 | $11,232,000 |
| Other Non Current Assets | $153,000 | $153,000 | $435,000 | $5,740,000 |
| Current Assets | $67,286,000 | $107,276,000 | $131,208,000 | $113,570,000 |
| Other Current Assets | $1,634,000 | $1,911,000 | $4,178,000 | $3,379,000 |
| Receivables | $25,387,000 | $52,476,000 | $50,697,000 | $1,084,000 |
| Other Receivables | $28,000 | $3,085,000 | $1,545,000 | $1,084,000 |
| Cash Cash Equivalents And Short Term Investments | $40,265,000 | $52,889,000 | $76,333,000 | $109,107,000 |
| Cash And Cash Equivalents | $40,265,000 | $52,889,000 | $76,333,000 | $109,107,000 |
| Cash Equivalents | $39,672,000 | $52,258,000 | - | - |
| Cash Financial | $593,000 | $631,000 | - | - |
| Non Current Accounts Receivable | - | - | $46,590,000 | - |
| Prepaid Assets | - | - | - | - |
| Taxes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $2,895,000 | $4,297,000 | $5,543,000 | $6,647,000 |
| Long Term Debt And Capital Lease Obligation | $939,000 | $2,551,000 | $3,825,000 | $4,957,000 |
| Current Debt And Capital Lease Obligation | $1,956,000 | $1,746,000 | $1,718,000 | $1,690,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,898,000 | $64,420,000 | $75,496,000 | $48,868,000 |
| Total Non Current Liabilities Net Minority Interest | $1,030,000 | $15,346,000 | $38,343,000 | $27,219,000 |
| Other Non Current Liabilities | $91,000 | - | $87,000 | $96,000 |
| Derivative Product Liabilities | $0 | $576,000 | $23,606,000 | $12,425,000 |
| Non Current Deferred Liabilities | $0 | $12,219,000 | $10,825,000 | $9,741,000 |
| Current Liabilities | $8,868,000 | $49,074,000 | $37,153,000 | $21,649,000 |
| Current Deferred Liabilities | $258,000 | $22,124,000 | $27,113,000 | $10,369,000 |
| Payables And Accrued Expenses | $6,654,000 | $25,204,000 | $8,322,000 | $9,590,000 |
| Payables | $1,076,000 | $7,480,000 | $1,765,000 | $617,000 |
| Total Tax Payable | $383,000 | $174,000 | $387,000 | $0 |
| Income Tax Payable | $383,000 | $174,000 | $387,000 | $0 |
| Accounts Payable | $693,000 | $7,306,000 | $1,378,000 | $617,000 |
| Equity | ||||
| Common Stock Equity | $59,021,000 | $46,123,000 | $106,894,000 | $75,934,000 |
| Total Equity Gross Minority Interest | $59,021,000 | $46,123,000 | $106,894,000 | $75,934,000 |
| Stockholders Equity | $59,021,000 | $46,123,000 | $106,894,000 | $75,934,000 |
| Retained Earnings | $-451,066,000 | $-459,638,000 | $-391,072,000 | $-413,878,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $0 |
| Preferred Stock Equity | - | - | - | - |
| Other Equity Adjustments | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $56,414,657 | $54,593,527 | $52,999,680 | $52,456,195 |
| Share Issued | $56,414,657 | $54,593,527 | $52,999,680 | $52,456,195 |
| Tangible Book Value | $59,021,000 | $46,123,000 | $106,894,000 | $75,934,000 |
| Invested Capital | $59,021,000 | $46,123,000 | $106,894,000 | $75,934,000 |
| Working Capital | $58,418,000 | $58,202,000 | $94,055,000 | $91,921,000 |
| Capital Lease Obligations | $2,895,000 | $4,297,000 | $5,543,000 | $6,647,000 |
| Total Capitalization | $59,021,000 | $46,123,000 | $106,894,000 | $75,934,000 |
| Additional Paid In Capital | $510,031,000 | $505,706,000 | $497,913,000 | $489,760,000 |
| Capital Stock | $56,000 | $55,000 | $53,000 | $52,000 |
| Common Stock | $56,000 | $55,000 | $53,000 | $52,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $12,219,000 | $10,825,000 | $9,741,000 |
| Long Term Capital Lease Obligation | $939,000 | $2,551,000 | $3,825,000 | $4,957,000 |
| Current Deferred Revenue | $258,000 | $22,124,000 | $27,113,000 | $10,369,000 |
| Current Capital Lease Obligation | $1,956,000 | $1,746,000 | $1,718,000 | $1,690,000 |
| Current Accrued Expenses | $5,578,000 | $17,724,000 | $6,557,000 | $8,973,000 |
| Net PPE | $1,480,000 | $3,114,000 | $4,157,000 | $5,492,000 |
| Gross PPE | $1,480,000 | $3,114,000 | $7,775,000 | $8,744,000 |
| Other Properties | $1,480,000 | $3,114,000 | $5,493,000 | $6,462,000 |
| Duefrom Related Parties Current | $25,359,000 | $49,391,000 | $49,152,000 | $0 |
| Duefrom Related Parties Non Current | - | $0 | $46,590,000 | - |
| Accumulated Depreciation | - | $-3,620,000 | $-3,618,000 | $-3,252,000 |
| Leases | - | $1,636,000 | $1,636,000 | $1,636,000 |
| Machinery Furniture Equipment | - | $646,000 | $646,000 | $646,000 |
| Properties | - | $0 | $0 | $0 |
| Other Short Term Investments | - | - | - | $0 |
| Construction In Progress | - | - | - | - |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,624,000 | $-23,444,000 | $-32,995,000 | $-7,731,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,624,000 | $-23,444,000 | $-32,995,000 | $-7,731,000 |
| Cash Flow From Continuing Operating Activities | $-12,624,000 | $-23,444,000 | $-32,995,000 | $-7,731,000 |
| Operating Gains Losses | - | - | - | $2,674,000 |
| Investing Activities | ||||
| Investing Cash Flow | - | - | $0 | $33,807,000 |
| Cash Flow From Continuing Investing Activities | - | - | $0 | $33,807,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | - | $0 | $221,000 | $24,512,000 |
| Financing Cash Flow | - | $0 | $221,000 | $-29,553,000 |
| Cash Flow From Continuing Financing Activities | - | $0 | $221,000 | $-29,553,000 |
| Net Common Stock Issuance | - | $0 | $221,000 | $24,512,000 |
| Common Stock Issuance | - | $0 | $221,000 | $24,512,000 |
| Net Other Financing Charges | - | - | - | $-54,485,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $40,265,000 | $52,889,000 | $76,333,000 | $109,107,000 |
| Beginning Cash Position | $52,889,000 | $76,333,000 | $109,107,000 | $112,584,000 |
| Changes In Cash | $-12,624,000 | $-23,444,000 | $-32,774,000 | $-3,477,000 |
| Change In Working Capital | $-27,156,000 | $36,284,000 | $-70,375,000 | $22,087,000 |
| Change In Other Working Capital | $-34,661,000 | $-26,625,000 | $29,009,000 | $21,892,000 |
| Change In Other Current Liabilities | $-1,311,000 | $-1,333,000 | $-1,113,000 | $-730,000 |
| Change In Other Current Assets | $24,032,000 | $46,633,000 | $-95,743,000 | $-3,000 |
| Change In Payables And Accrued Expense | $-18,550,000 | $16,882,000 | $-1,268,000 | $-5,861,000 |
| Change In Accrued Expense | $-12,146,000 | $11,167,000 | $-2,416,000 | $-5,377,000 |
| Change In Payable | $-6,404,000 | $5,715,000 | $1,148,000 | $-484,000 |
| Change In Account Payable | $-6,613,000 | $5,928,000 | $761,000 | $-484,000 |
| Change In Tax Payable | $209,000 | $-213,000 | $387,000 | $0 |
| Change In Income Tax Payable | $209,000 | $-213,000 | $387,000 | $0 |
| Change In Prepaid Assets | $277,000 | $2,267,000 | $-799,000 | $5,242,000 |
| Change In Receivables | $3,057,000 | $-1,540,000 | $-461,000 | $1,547,000 |
| Other Non Cash Items | $1,048,000 | $1,043,000 | $969,000 | $3,283,000 |
| Stock Based Compensation | $4,325,000 | $7,793,000 | $7,932,000 | $9,123,000 |
| Asset Impairment Charge | $587,000 | $0 | $5,306,000 | $635,000 |
| Depreciation Amortization Depletion | $0 | $2,000 | $367,000 | $869,000 |
| Depreciation And Amortization | $0 | $2,000 | $367,000 | $869,000 |
| Net Income From Continuing Operations | $8,572,000 | $-68,566,000 | $22,806,000 | $-46,415,000 |
| Income Tax Paid Supplemental Data | - | $99,000 | $2,212,000 | $0 |
| Proceeds From Stock Option Exercised | - | - | $0 | $420,000 |
| Net Investment Purchase And Sale | - | - | $0 | $33,807,000 |
| Sale Of Investment | - | - | $0 | $60,777,000 |
| Purchase Of Investment | - | - | $0 | $-26,970,000 |
| Amortization Of Securities | - | - | $0 | $13,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | $0 | $10,000 |
| Gain Loss On Investment Securities | - | - | - | $-917,000 |
| Net PPE Purchase And Sale | - | - | - | - |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-11